Cytek BiosciencesCTKB +0.11%71 FCF Margin % is -11.19% as of Mar. 2026. GuruFocus rates CTKB with a GF Score™ of 71/100 and a GF Value™ of $5.82 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Cytek Biosciences ranks worse than 61.1% on this metric.
The historical rank and industry rank for Cytek Biosciences's FCF Margin % or its related term are showing as below:
CTKB'
s FCF Margin % Range Over the Past 10 Years
Min: -25.43 Med: 0.21 Max: 14.66
Current: -6.29
During the past 7 years, the highest FCF Margin % of Cytek Biosciences was 14.66%. The lowest was -25.43%. And the median was 0.21%.
CTKB's FCF Margin % is ranked worse than 61.1% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: -0.03
vs CTKB: -6.29
Cytek Biosciences FCF Margin % Related Terms
Cytek Biosciences FCF Margin % Historical Data
* Premium members only.
The historical data trend for Cytek Biosciences's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Cytek Biosciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cytek Biosciences FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cytek Biosciences's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Cytek Biosciences's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cytek Biosciences (CTKB) has a FCF Margin % of -11.19% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Cytek Biosciences and its competitors. According to the industry distribution chart, Cytek Biosciences ranks #498 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 61.1%.
Is Cytek Biosciences' FCF Margin % too high?
Cytek Biosciences' current FCF Margin % is -11.19%. Based on the distribution chart, Cytek Biosciences ranks #498 out of 815 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Cytek Biosciences has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cytek Biosciences' FCF Margin % compare to BBNX and TCMD?
According to the Medical Devices & Instruments industry distribution chart, Cytek Biosciences ranks #498 out of 815 companies for FCF Margin %. This places Cytek Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Cytek Biosciences and its competitors. Cytek Biosciences's current FCF Margin % is -11.19%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cytek Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Cytek Biosciences (CTKB) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.82, compared to a current price of $4.46 — trading 23.4% below its estimated fair value. The current FCF Margin % is -11.19%. Cytek Biosciences' overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Cytek Biosciences (CTKB), the current FCF Margin % is -11.19% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cytek Biosciences (CTKB) Overvalued in 2026?
Based on GuruFocus' analysis, Cytek Biosciences stock appears to be undervalued.
The current stock price of $4.46 is trading 23.4% below its estimated GF Value™ of $5.82.
GuruFocus considers Cytek Biosciences to be Modestly Undervalued.
Key valuation signals for CTKB:
FCF Margin %: -11.19%
GF Value™: $5.82 vs. price of $4.46 (23.4% below fair value)
No single metric tells the full story. See the CTKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
71GF Score
Get the complete analysis for CTKB
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTKB has been successfully added to your 
